302 patents
Page 11 of 16
Utility
1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
11 May 21
Tord Bertil Inghardt, Petra Johannesson, Ulrik Jurva, Erik Michaelsson, Eva-Lotte Lindstedt-Alstermark, Nicholas Tomkinson, Jeffrey Paul Stonehouse, Li-Ming Gan
Filed: 15 Jun 18
Utility
Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors
11 May 21
Johan Olof Broddefalk, Hans Fredrik Emtenâs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
Filed: 30 Oct 19
Utility
Novel Biomarkers and Methods of Treating Cancer
6 May 21
Biomarkers for the treatment of pathological conditions associated with the PI3K pathway, such as cancer, and methods of using inhibitors of upstream components of the PI3K pathway, such as PI3K-α inhibitors or AKT inhibitors, are described.
Alvaro AVIVAR VALDERAS, Francisco Humberto CRUZALEGUI, Kevin HUDSON, Robert Kenneth McEWEN
Filed: 16 Sep 16
Utility
2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE Compounds
6 May 21
The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant).
Sam BUTTERWORTH, Maurice Raymond Verschoyle FINLAY, Richard Andrew WARD, Heather Marie REDFEARN, Vasantha Krishna KADAMBAR, Chandrasekhara Reddy CHINTAKUNTLA, Andiappan MURUGAN, Claudio Edmundo CHUAQUI
Filed: 12 Nov 20
Utility
Inhaler counter
4 May 21
An inhaler for delivery of a medicament by inhalation is disclosed.
Simon Christopher Berry, Jonas Christiansen, Svend Erik Elgaard, Esben W. Johansen, Claus Schmidt Moller, Jorgen Rasmussen, Henrik Hougaard Vilstrup, William Richard Treneman
Filed: 12 Sep 18
Utility
Improved Process for the Preparation of Osimertinib (AZD9291) or a Salt Thereof, and "AZD9291 Aniline" or a Salt Thereof
29 Apr 21
An improved chemical process for the manufacture of the compound of Formula (I), which is useful, for example, as a late-stage chemical intermediate in the production of osimertinib (AZD9291) and pharmaceutically acceptable salts thereof.
Alistair John BOYD, Alexander TELFORD
Filed: 31 Jan 17
Utility
Synthesis of MCL-1 Inhibitor
29 Apr 21
Craig Robert STEWART, Simon HARDY, Andrew STARK, Alexander HIRD, Qing YE, Xiaolan ZHENG, Cati FERRAR, Jan KOEK, Debasis HAZRA
Filed: 29 Mar 18
Utility
Compounds
27 Apr 21
Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
Filed: 25 Nov 19
Utility
Pharmaceutical Composition Comprising a Potent Inhibitor of URAT1
22 Apr 21
The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonapthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
Filed: 31 Aug 20
Utility
Topically Applicable Pharmaceutical Preparation
22 Apr 21
A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described.
Christina BOLLE, Rudolf LINDER
Filed: 3 Jun 20
Utility
Methods of treating heart failure with reduced ejection fraction
13 Apr 21
The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Anna Maria Langkilde
Filed: 9 Mar 20
Utility
Methods for Treating Late-onset Asthma Using Benralizumab
1 Apr 21
Provided herein are methods of treating patients with late-onset asthma or asthma falling within Severe Asthma Research Program (SARP) clinical cluster 3 or 5 comprising administering to the patient a therapeutically effective amount of the anti-interleukin-5 receptor (IL-5R) antibody, benralizumab, or an antigen-binding fragment thereof.
Ian HIRSCH, Paul NEWBOLD
Filed: 25 Sep 20
Utility
JAK1 selective inhibitors
30 Mar 21
Karl Magnus Nilsson, Annika Birgitta Margareta Astrand, Anna Ingrid Kristina Berggren, Johan R. Johansson, Matti Juhani Lepisto, Sameer Pralhad Kawatkar, Qibin Su, Jason Grant Kettle
Filed: 16 Jan 18
Utility
Chemical compounds
30 Mar 21
Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang
Filed: 28 Jan 20
Utility
(S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor
30 Mar 21
Matthew Perry, Christian Tyrchan, Konstantinos Karabelas, Antonios Nikitidis, Mickael Mogemark, Jens Petersen, Peter Bold, Ulf Borjesson
Filed: 21 Sep 17
Utility
Computer system and method for generating trigger alerts to maximize interactions with healthcare providers
23 Mar 21
A pharmaceutical company may employ a computer system that is configured to train a machine learning model for predicting a next time in the future at which a given type of treatment decision is likely to be made for a patient, use the trained machine learning model to analyze anonymized patient data for patients treated by a given health care provider (HCP) in order to predict a next time in the future at which the given HCP is likely to make a given type of treatment decision for at least one patient, and then responsively generate a trigger alert suggesting that the given HCP be visited prior to the predicted next time to deliver a message related to the given type of treatment decision, which may in turn be delivered to a target of the trigger alert.
Kishore Kumar
Filed: 23 Aug 18
Utility
Chemical compounds
23 Mar 21
Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
Filed: 10 May 19
Utility
Inducible modification of a cell genome
16 Mar 21
The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
Marcello Maresca, Mohammad Bohlooly-Yeganeh, Himjyot Jaiswal, Lorenz M. Mayr, Xiufeng Xu
Filed: 14 Oct 16
Utility
Composition for Inhalation
11 Mar 21
The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases.
Nayna Govind, Maria Marlow
Filed: 27 Mar 20
Utility
Compositions and Methods for Treating Late Stage Lung Cancer
11 Mar 21
Disclosed are methods for treating extensive-stage small-cell lung cancer (ES-SCLC) with an antibody that inhibits PD1/PD-L1 activity in combination with etoposide and a platinum-based therapeutic agent.
HAIYI JIANG, YIFAN HUANG, PHILLIP DENNIS, NORAH SHIRE, JON ARMSTRONG
Filed: 4 Sep 20